Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Endocrinology
•
Thyroid Disorders
In which specific scenarios would you consider transitioning from oral to intravenous thyroid hormone replacement in the outpatient setting?
Related Questions
Should a different weight-based dosing algorithm for levothyroxine therapy be considered in women versus men given higher incidence of iatrogenic thyrotoxicosis in women?
What is the optimal frequency for follow-up of low-risk sub-centimeter thyroid cysts?
Statistically speaking, approximately what percentage of thyroid nodule FNA biopsies are Bethesda category 1 (= nondiagnostic or unsatisfactory), and what percentage are indeterminate (Bethesda category 3 and 4)?
How do you counsel patients that are positive for both stimulatory and inhibitory autoimmune thyroid markers (TRAb, TSI and TPO Ab) regarding their likelihood of flipping from hyperthyroidism to hypothyroidism?
How do you counsel patients on the risk of hypothyroidism after radioactive ablation for hot nodules?
How do you evaluate and manage Rezdiffra (resmetirom)-induced abnormal thyroid function tests?
What TSH cut off do you use to determine the need for levothyroxine supplementation in a pregnant patient with positive TPO antibodies?
For Graves' disease patients undergoing radioactive iodine ablation, what is the preferred approach to steroid prophylaxis for Graves' orbitopathy?
What is the evidence, if any, for the use of low dose naltrexone in the treatment of autoimmune thyroiditis?
Would you consider extending Tepezza treatment for thyroid eye disease management in patients with incomplete response?
